Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Genuardi

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Journal of Clinical Medicine|September 21, 2018
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid MalignanciesIrene Dogliotti, Daniela Drandi, Elisa Genuardi, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2022
Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin LymphomasElisa Genuardi, Beatrice Alessandria, Aurora Maria Civita, et al.
Current Treatment Options in Oncology|November 8, 2018
Minimal Residual Disease in Indolent Lymphomas: A Critical AssessmentDaniele Grimaldi, Elisa Genuardi, Martina Ferrante, et al.
Hematological Oncology|March 10, 2010
Telomeres and telomerase in normal and malignant B-cellsChiara Lobetti-Bodoni, Elisa Bernocco, Elisa Genuardi, et al.
Frontiers in Oncology|March 18, 2020
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?Niccolo Bolli, Elisa Genuardi, Bachisio Ziccheddu, et al.
Frontiers in Oncology|July 12, 2019
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical PracticeSara Galimberti, Elisa Genuardi, Francesco Mazziotta, et al.
Therapeutic Advances in Hematology|June 5, 2013
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphomaChiara Lobetti-Bodoni, Barbara Mantoan, Luigia Monitillo, et al.
BMC Bioinformatics|November 25, 2017
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing dataMarco Beccuti, Elisa Genuardi, Greta Romano, et al.
British Journal of Haematology|May 18, 2021
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trialElisa Genuardi, Greta Romano, Marco Beccuti, et al.
Current Issues in Molecular Biology|January 30, 2026
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic LeukemiaChiara Pighi, Alessandro Gasparetto, Elisa Genuardi, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Journal of Clinical Medicine|September 21, 2018
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid MalignanciesIrene Dogliotti, Daniela Drandi, Elisa Genuardi, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2022
Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin LymphomasElisa Genuardi, Beatrice Alessandria, Aurora Maria Civita, et al.
Current Treatment Options in Oncology|November 8, 2018
Minimal Residual Disease in Indolent Lymphomas: A Critical AssessmentDaniele Grimaldi, Elisa Genuardi, Martina Ferrante, et al.
Hematological Oncology|March 10, 2010
Telomeres and telomerase in normal and malignant B-cellsChiara Lobetti-Bodoni, Elisa Bernocco, Elisa Genuardi, et al.
Frontiers in Oncology|March 18, 2020
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?Niccolo Bolli, Elisa Genuardi, Bachisio Ziccheddu, et al.
Frontiers in Oncology|July 12, 2019
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical PracticeSara Galimberti, Elisa Genuardi, Francesco Mazziotta, et al.
Therapeutic Advances in Hematology|June 5, 2013
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphomaChiara Lobetti-Bodoni, Barbara Mantoan, Luigia Monitillo, et al.
BMC Bioinformatics|November 25, 2017
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing dataMarco Beccuti, Elisa Genuardi, Greta Romano, et al.
British Journal of Haematology|May 18, 2021
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trialElisa Genuardi, Greta Romano, Marco Beccuti, et al.
Current Issues in Molecular Biology|January 30, 2026
Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic LeukemiaChiara Pighi, Alessandro Gasparetto, Elisa Genuardi, et al.
Pageof 5